AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter and nine months ended 31 December 2020

'Rs in lakhs except for earnings per share data

Sl No.	Particulars	3 months ended 31/12/2020	Previous 3 months ended 30/09/2020	Corresponding 3 months ended in the previous year 31/12/2019	9 months ended 31/12/2020	9 months ended 31/12/2019	Year ended 31/03/2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Revenue**						
	a) Revenue from operations	20,025.20	20,947.71	22,386.28	60,330.67	63,690.72	83,180.91
	b) Other income	292.82	471.25	346.15	1,028.88	961.15	1,298.79
	Total Income	**20,318.02**	**21,418.96**	**22,732.43**	**61,359.55**	**64,651.87**	**84,479.70**
2	**Expenses**						
	(a) Cost of materials consumed	2,619.86	2,397.68	2,164.70	7,102.92	5,368.39	7,021.07
	(b) Purchase of stock-in-trade	2,135.03	6,929.50	7,675.58	13,775.75	18,701.43	27,423.30
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,075.59	(1,571.66)	(1,708.52)	963.11	(1,518.64)	(3,920.84)
	(d) Employee benefits expense	5,505.53	5,564.47	5,255.49	16,704.75	15,545.25	21,670.07
	(e) Depreciation expense	511.04	462.20	477.12	1,429.40	1,403.91	1,858.36
	(f) Allowance for expected credit loss (net)	21.37	186.98	42.11	190.43	92.58	158.27
	(g) Selling, marketing and distribution expense	1,432.89	1,148.79	1,169.65	3,505.54	4,269.14	5,575.57
	(h) Other expenses	3,160.58	2,716.33	4,110.91	8,581.01	10,644.00	13,184.19
	(i) Finance cost	26.04	27.68	27.13	81.12	85.03	113.67
	Total expenses	**17,487.93**	**17,861.97**	**19,214.18**	**52,334.03**	**54,591.09**	**73,083.66**
3	**Profit before exceptional and extraordinary items and tax (1-2)**	**2,830.09**	**3,556.99**	**3,518.26**	**9,025.52**	**10,060.78**	**11,396.04**
4	Exceptional items	-	-	-	-	-	-
5	**Profit before extraordinary items and tax (3+4)**	**2,830.09**	**3,556.99**	**3,518.26**	**9,025.52**	**10,060.78**	**11,396.04**
6	Extraordinary items	-	-	-	-	-	-
7	**Profit before tax (5+6)**	**2,830.09**	**3,556.99**	**3,518.26**	**9,025.52**	**10,060.78**	**11,396.04**
8	**Tax expense**						
	- Current tax	773.62	994.75	881.34	2,627.91	2,665.55	3,150.93
	- Deferred tax	(48.69)	(71.60)	(33.25)	(204.85)	1,132.00	1,024.02
	Total tax expense	**724.93**	**923.15**	**848.09**	**2,423.06**	**3,797.55**	**4,174.95**
9	**Profit after tax (7-8)**	**2,105.16**	**2,633.84**	**2,670.16**	**6,602.46**	**6,263.23**	**7,221.09**
10	**Other comprehensive income/(loss)**						
	A. Items that will not be reclassified to profit or loss						
	Re-measurement gains/(losses) on post employment benefit obligations	(5.20)	(4.27)	107.26	88.71	(351.63)	(657.70)
	Income tax effect on above	1.31	1.08	(27.00)	(22.33)	88.50	165.53
	Total other comprehensive income/ (loss), net of income tax	**(3.89)**	**(3.19)**	**80.27**	**66.38**	**(263.13)**	**(492.17)**
	Total comprehensive income for the period (9+10)	**2,101.27**	**2,630.65**	**2,750.43**	**6,668.84**	**6,000.10**	**6,728.92**
11	**Paid-up equity share capital** (Face value of Rs 2/- per equity share)	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**
12	Reserves (excluding revaluation reserves as per balance sheet)	-	-	-	-	-	35,943.62
13	**Earnings per equity share of Rs 2/- each (basic and diluted)**	**8.42**	**10.54**	**10.68**	**26.41**	**25.05**	**28.88**

PRADIP M KANAKIA

Digitally signed by PRADIP M KANAKIA
Date: 2021.02.08
17:46:47 +05'30'

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of unaudited financial results for the quarter and nine months ended 31 December 2020

Notes:

1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.

3 **Impact of COVID-19 Pandemic**
The Company, which is in the business of manufacture and supply of essential goods, has been assessing the impact of COVID-19 pandemic on its business and believes that the pandemic does not have a material impact on the current or future operations, financial position and liquidity of the Company. Management has considered all possible impact of known events arising from the pandemic in the preparation of these financial results and will continue to closely monitor the situation.

4 The Indian Parliament has approved the Code on Social Security, 2020 ("Code") which may likely impact the contributions made by the Company towards employee's provident fund and gratuity. The effective date from which the Code is applicable and the rules to be framed under the Code are yet to be notified. In view of this, impact of the change, if any, will be assessed and accounted in the period in which the Code and the rules thereunder are notified.

5 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.

6 This statement of finanacial results was reviewed and recommended by the Audit Commiltee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 08 February 2021. The Statutory Auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 31 December 2020.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Gagandeep Singh Bedi
Managing Director

Place: Bengaluru
Date: 08 February, 2021